Bristol Myers Cancer Clinical Trial 2026: RYZ101 Meets Goal
Bristol Myers cancer clinical trial 2026: RYZ101 met its Phase 3 endpoint in neuroendocrine tumours, but the effect size and safety data are not yet public.
Bristol Myers cancer clinical trial 2026: RYZ101 met its Phase 3 endpoint in neuroendocrine tumours, but the effect size and safety data are not yet public.